BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frantz C, Auffray C, Avouac J, Allanore Y. Regulatory T Cells in Systemic Sclerosis. Front Immunol 2018;9:2356. [PMID: 30374354 DOI: 10.3389/fimmu.2018.02356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Agarbati S, Benfaremo D, Viola N, Paolini C, Svegliati Baroni S, Funaro A, Moroncini G, Malavasi F, Gabrielli A. Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis. Front Immunol 2022;13:1072462. [PMID: 36618427 DOI: 10.3389/fimmu.2022.1072462] [Reference Citation Analysis]
2 Kim S, Park HJ, Lee SI. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential. Int J Mol Sci 2022;23. [PMID: 36555792 DOI: 10.3390/ijms232416154] [Reference Citation Analysis]
3 Allanore Y. Esclerodermia sistémica: epidemiología, fisiopatología y clínica. EMC - Aparato Locomotor 2022;55:1-27. [DOI: 10.1016/s1286-935x(22)47185-1] [Reference Citation Analysis]
4 Fang D, Chen B, Lescoat A, Khanna D, Mu R. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol 2022. [DOI: 10.1038/s41584-022-00864-7] [Reference Citation Analysis]
5 Wang H, Li Y, Yue Z, Liu Y, Chen Q, Hu D, Han J, Mishra SK. Adipose-Derived Stem Cell Exosomes Inhibit Hypertrophic Scaring Formation by Regulating Th17/Treg Cell Balance. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/9899135] [Reference Citation Analysis]
6 Sakkas LI, Bogdanos DP. The Role of T Cells in Systemic Sclerosis: An Update. Immuno 2022;2:534-547. [DOI: 10.3390/immuno2030034] [Reference Citation Analysis]
7 Jin W, Zheng Y, Zhu P. T cell abnormalities in systemic sclerosis. Autoimmun Rev 2022;:103185. [PMID: 36031049 DOI: 10.1016/j.autrev.2022.103185] [Reference Citation Analysis]
8 Kawashima-vasconcelos MY, Santana-gonçalves M, Zanin-silva DC, Malmegrim KCR, Oliveira MC. Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis. Front Immunol 2022;13:941011. [DOI: 10.3389/fimmu.2022.941011] [Reference Citation Analysis]
9 Ni S, Ji T, Dong J, Chen F, Feng H, Zhao H, Chen D, Ma W. Immune Cells in Pulmonary Arterial Hypertension. Heart Lung Circ 2022;31:934-43. [PMID: 35361533 DOI: 10.1016/j.hlc.2022.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chepy A, Bourel L, Koether V, Launay D, Dubucquoi S, Sobanski V. Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis? Front Immunol 2022;13:930970. [DOI: 10.3389/fimmu.2022.930970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liu Y, Shi JZ, Jiang R, Liu SF, He YY, van der Vorst EPC, Weber C, Döring Y, Yan Y. Regulatory T Cell-Related Gene Indicators in Pulmonary Hypertension. Front Pharmacol 2022;13:908783. [PMID: 35712711 DOI: 10.3389/fphar.2022.908783] [Reference Citation Analysis]
12 Kobayashi S, Nagafuchi Y, Shoda H, Fujio K. The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. Front Immunol 2022;13:900638. [PMID: 35686127 DOI: 10.3389/fimmu.2022.900638] [Reference Citation Analysis]
13 Burg N, Salmon JE, Hla T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol 2022. [PMID: 35508810 DOI: 10.1038/s41584-022-00784-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 De Zorzi E, Spagnolo P, Cocconcelli E, Balestro E, Iaccarino L, Gatto M, Benvenuti F, Bernardinello N, Doria A, Maher TM, Zanatta E. Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. Clin Rev Allergy Immunol 2022. [PMID: 35303257 DOI: 10.1007/s12016-022-08926-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Frantz C, Cauvet A, Durand A, Gonzalez V, Pierre R, Do Cruzeiro M, Bailly K, Andrieu M, Orvain C, Avouac J, Ottaviani M, Thuillet R, Tu L, Guignabert C, Lucas B, Auffray C, Allanore Y. IL-2-related regulatory CD4 T-cell deficiency leads to the development of lung fibrosis and vascular remodeling. Arthritis Rheumatol 2022. [PMID: 35255201 DOI: 10.1002/art.42111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci 2022. [PMID: 35234358 DOI: 10.1002/kjm2.12505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zeng Z, Wang Y, Xiao Y, Zheng J, Liu R, He X, Yu J, Tang B, Qiu X, Tang R, Shi Y, Xiao R. Overexpression of OASL upregulates TET1 to induce aberrant activation of CD4+ T cells in systemic sclerosis via IRF1 signaling. Arthritis Res Ther 2022;24. [DOI: 10.1186/s13075-022-02741-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Boleto G, Avouac J, Allanore Y. The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. Ther Adv Musculoskelet Dis 2022;14:1759720X211066686. [PMID: 35111241 DOI: 10.1177/1759720X211066686] [Reference Citation Analysis]
19 Benfaremo D, Svegliati S, Paolini C, Agarbati S, Moroncini G. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2022;10:163. [DOI: 10.3390/biomedicines10010163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Winkler J, Herzog EL. Adaptive Immunity in Interstitial Lung Disease. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00018-4] [Reference Citation Analysis]
21 Ge Y, Luo J, Li D, Li C, Huang J, Yu H, Lin X, Li Y, Man M, Zhang J, Zhang J, Hu L. Deficiency of vitamin D receptor in keratinocytes augments dermal fibrosis and inflammation in a mouse model of HOCl-induced scleroderma. Biochem Biophys Res Commun 2021;591:1-6. [PMID: 34986435 DOI: 10.1016/j.bbrc.2021.12.085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Shen CY, Lu CH, Wu CH, Li KJ, Kuo YM, Hsieh SC, Yu CL. Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis. Cells 2021;10:3402. [PMID: 34943909 DOI: 10.3390/cells10123402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Avouac J. Cellules CAR-T : extension aux maladies auto-immunes en rhumatologie. Revue du Rhumatisme 2021;88:A1-A6. [DOI: 10.1016/j.rhum.2021.09.001] [Reference Citation Analysis]
24 Kolios AGA, Tsokos GC, Klatzmann D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat Rev Rheumatol 2021;17:749-66. [PMID: 34728817 DOI: 10.1038/s41584-021-00707-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
25 Tian W, Jiang SY, Jiang X, Tamosiuniene R, Kim D, Guan T, Arsalane S, Pasupneti S, Voelkel NF, Tang Q, Nicolls MR. The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. Front Immunol 2021;12:684657. [PMID: 34489935 DOI: 10.3389/fimmu.2021.684657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
26 Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clin Rev Allergy Immunol 2021. [PMID: 34468946 DOI: 10.1007/s12016-021-08891-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Beurier P, Ricard L, Eshagh D, Malard F, Siblany L, Fain O, Mohty M, Gaugler B, Mekinian A. TFH cells in systemic sclerosis. J Transl Med 2021;19:375. [PMID: 34461933 DOI: 10.1186/s12967-021-03049-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis 2021. [PMID: 34272836 DOI: 10.1002/iid3.475] [Reference Citation Analysis]
29 Miura S, Watanabe Y, Saigusa R, Yamashita T, Nakamura K, Hirabayashi M, Miyagawa T, Yoshizaki A, Trojanowska M, Sato S, Asano Y. Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma. Arthritis Res Ther 2021;23:137. [PMID: 33964960 DOI: 10.1186/s13075-021-02520-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Stifano G, De Palma R. Editorial: Etiopathogenesis of Systemic Sclerosis: An Update. Front Immunol 2021;12:663381. [PMID: 33828566 DOI: 10.3389/fimmu.2021.663381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Awaji K, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Norimatsu Y, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y. A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis. Exp Dermatol 2021;30:959-65. [PMID: 33719171 DOI: 10.1111/exd.14320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Vasilev V, Ristić A. Cardiovascular diagnosis in patients with rheumatoid arthritis, primary Sjögren's syndrome, systemic sclerosis and systemic lupus erhytematosus. Medicinski podmladak 2021;72:1-7. [DOI: 10.5937/mp72-34157] [Reference Citation Analysis]
33 Du Y, Fang Q, Zheng SG. Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics. Adv Exp Med Biol 2021;1278:1-31. [PMID: 33523440 DOI: 10.1007/978-981-15-6407-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Boothby IC, Cohen JN, Rosenblum MD. Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair. Sci Immunol 2020;5:eaaz9631. [PMID: 32358172 DOI: 10.1126/sciimmunol.aaz9631] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 17.0] [Reference Citation Analysis]
35 Aung WW, Wang C, Xibei J, Horii M, Mizumaki K, Kano M, Okamura A, Kobayashi T, Matsushita T. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. J Dermatol Sci 2021;101:174-84. [PMID: 33451905 DOI: 10.1016/j.jdermsci.2020.12.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
36 Zhang R, Miao J, Zhu P. Regulatory T cell heterogeneity and therapy in autoimmune diseases. Autoimmun Rev 2021;20:102715. [PMID: 33197573 DOI: 10.1016/j.autrev.2020.102715] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
37 Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L. Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement. Cells. 2020;9. [PMID: 32947843 DOI: 10.3390/cells9092106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
38 Shi Y, Zeng Z, Yu J, Tang B, Tang R, Xiao R. The aryl hydrocarbon receptor: An environmental effector in the pathogenesis of fibrosis. Pharmacol Res 2020;160:105180. [PMID: 32877693 DOI: 10.1016/j.phrs.2020.105180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
39 Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med 2020;9:E2687. [PMID: 32825112 DOI: 10.3390/jcm9092687] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
40 Mannie MD, DeOca KB, Bastian AG, Moorman CD. Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells. Cell Immunol 2020;355:104173. [PMID: 32712270 DOI: 10.1016/j.cellimm.2020.104173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
41 Thiagarajan D, Oparina N, Lundström S, Zubarev R, Sun J, Alarcon-Riquelme M, Frostegård J; PRECISESADS Clinical Consortium. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Sci Rep 2020;10:11010. [PMID: 32620913 DOI: 10.1038/s41598-020-66981-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Allanore Y. Stem cells: Hope for systemic sclerosis patients? Joint Bone Spine 2020;87:285-8. [DOI: 10.1016/j.jbspin.2019.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med 2020;201:650-60. [PMID: 31841044 DOI: 10.1164/rccm.201903-0563CI] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 19.7] [Reference Citation Analysis]
44 Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol 2020;72:125-36. [PMID: 31342624 DOI: 10.1002/art.41055] [Cited by in Crossref: 107] [Cited by in F6Publishing: 115] [Article Influence: 26.8] [Reference Citation Analysis]
45 Brilland B, Beauvillain C, Mazurkiewicz G, Rucay P, Roquelaure Y, Tabiasco J, Vinatier E, Riou J, Jeannin P, Renier G, Subra JF, Augusto JF. T Cell Dysregulation in Non-silicotic Silica Exposed Workers: A Step Toward Immune Tolerance Breakdown. Front Immunol 2019;10:2743. [PMID: 31824514 DOI: 10.3389/fimmu.2019.02743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Allanore Y. Les cellules-souches : un espoir dans la sclérodermie systémique ? Revue du Rhumatisme 2019;86:A33-A36. [DOI: 10.1016/s1169-8330(19)30356-4] [Reference Citation Analysis]
47 Boehncke WH, Brembilla NC. Autoreactive T-Lymphocytes in Inflammatory Skin Diseases. Front Immunol 2019;10:1198. [PMID: 31191553 DOI: 10.3389/fimmu.2019.01198] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
48 Göschl L, Scheinecker C, Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol 2019;41:301-14. [PMID: 30953162 DOI: 10.1007/s00281-019-00741-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]